<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, June 26, 2019 (HealthDay News) — Combining ivermectin cream (IVM) and doxycycline modified-release capsules (DMR) can improve response rates for patients with severe rosacea, according to a study recently published in the Journal of the American Academy of Dermatology<\/i>.<\/p>\n
Martin Schaller, M.D., from T\u00fcbingen University Hospital in Germany, and colleagues conducted a 12-week multicenter, randomized comparative trial involving adults with severe rosacea. A total of 273 participants were randomly assigned to IVM and DMR (combination arm) and IVM and placebo (monotherapy).<\/p>\n
The researchers found that IVM and DMR exhibited superior efficacy in reducing inflammatory lesions compared with monotherapy (\u221280.3 versus \u221273.6 percent; P = 0.032) and in the Investigator’s Global Assessment (IGA) score (P = 0.032). As of week 4, combination therapy had a faster onset of action; at week 12, significantly more patients achieved IGA 0 (11.9 versus 5.1 percent; P = 0.043) and 100 percent lesion reduction (17.8 versus 7.2 percent; P = 0.006) with combination therapy. The Clinician’s Erythema Assessment score, stinging\/burning, flushing episodes, Dermatology Life Quality Index, and ocular signs\/symptoms were reduced with both treatments, and both treatments were well-tolerated.<\/p>\n
“These study results suggest that using a combination of IVM and DMR, each once daily, along with a properly selected skin care regimen, can improve treatment results,” the authors write. “Ultimately, overall patient satisfaction was achieved more frequently in those subjects who utilized the combination therapy.”<\/p>\n
Several authors disclosed ties to pharmaceutical companies, including Galderma, which funded the study and provided the study product.<\/p>\n